Shots:
Ghryvelin (macimorelin) developed by Aeterna & its licensing partner, Consilient Health, is commercialized across the EU as the first oral test for the diagnosis of AGHD
This oral test is a ghrelin agonist & an active small molecule that measures the level of stimulated growth hormone in blood samples. Ghryvelin’s EU approval in 2019 was based on the P-III data demonstrating it to have better accuracy & favorable safety profile vs. standard ITT
Macimorelin is the US FDA & EU approved oral test for AGHD & is currently being marketed in the US as Macrilen by Aeterna’s licensing partner Novo Nordisk
Ref: Globenewswire | Image: Aeterna Zentaris
